Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
DAWN Stock Chart & Stats
$8.85
-$0.14(-1.13%)
At close: 4:00 PM EST
$8.85
-$0.14(-1.13%)
Day’s Range― - ―
52-Week Range$5.64 - $14.46
Previous CloseN/A
Volume175.11K
Average Volume (3M)2.23M
Market Cap
$1.06B
Enterprise Value$280.15M
Total Cash (Recent Filing)$451.58M
Total Debt (Recent Filing)$2.89M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Mar 09, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding102,675,500
10 Day Avg. Volume3,914,950
30 Day Avg. Volume2,230,139
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.36
Price to Sales (P/S)9.04
P/FCF Ratio-14.78
Enterprise Value/Market Cap0.26
Enterprise Value/Revenue2.10
Enterprise Value/Gross Profit2.34
Enterprise Value/Ebitda-1.98
Forecast
1Y Price Target
$23.57Price Target Upside166.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.03
Revenue Forecast (FY)$148.51M
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyThe acquisition of Mersana brings Emi Le, a B7 H4 directed Dolasynthen ADC, into Day One’s portfolio, which is seen as a smart advancement for the company.
Regulatory AdvancementsThe FDA has provided two Fast Track designations for Emi Le in TNBC and HER2 low post topo breast cancer, potentially simplifying regulatory discussions.
Revenue GrowthThe impressive 15% quarter-over-quarter growth in Ojemda revenue is driven by a substantial increase in prescriptions and new patient starts.
Bears Say
Competitive LandscapeThere are several peer programs in clinical development with B7-H4 targeting ADCs, which may pose competition for Day One's efforts.
Financial ImpactAcquiring an ADC platform for ~$100MN in upfront cash likely to negatively impact the trading multiple in the short term.
Market Adoption ChallengesGrowth stunting is primarily the main hindrance for market adoption of Ojemda.
Day One Biopharmaceuticals News
DAWN FAQ
What was Day One Biopharmaceuticals’s price range in the past 12 months?
Day One Biopharmaceuticals lowest stock price was $5.63 and its highest was $14.46 in the past 12 months.
What is Day One Biopharmaceuticals’s market cap?
Day One Biopharmaceuticals’s market cap is $1.06B.
When is Day One Biopharmaceuticals’s upcoming earnings report date?
Day One Biopharmaceuticals’s upcoming earnings report date is Mar 09, 2026 which is in 114 days.
How were Day One Biopharmaceuticals’s earnings last quarter?
Day One Biopharmaceuticals released its earnings results on Nov 04, 2025. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.297 by $0.107.
Is Day One Biopharmaceuticals overvalued?
According to Wall Street analysts Day One Biopharmaceuticals’s price is currently Undervalued.
Does Day One Biopharmaceuticals pay dividends?
Day One Biopharmaceuticals does not currently pay dividends.
What is Day One Biopharmaceuticals’s EPS estimate?
Day One Biopharmaceuticals’s EPS estimate is -0.19.
How many shares outstanding does Day One Biopharmaceuticals have?
Day One Biopharmaceuticals has 102,675,500 shares outstanding.
What happened to Day One Biopharmaceuticals’s price movement after its last earnings report?
Day One Biopharmaceuticals reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.297. Following the earnings report the stock price went up 25.205%.
Which hedge fund is a major shareholder of Day One Biopharmaceuticals?
Currently, no hedge funds are holding shares in DAWN
Day One Biopharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.57 (166.33% Upside)
$23.57 (166.33% Upside)
Blogger Sentiment
Bullish
DAWN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 5.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 5.0%
Last 30 Days ▲ 13.3%
Last 30 Days ▲ 13.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-40.40%
12-Months-Change
Fundamentals
Return on Equity
-30.16%
Trailing 12-Months
Asset Growth
-14.49%
Trailing 12-Months
Company Description
Day One Biopharmaceuticals
Day One Biopharmaceuticals (DAWN) is a clinical-stage biopharmaceutical company that focuses on developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. The company is dedicated to advancing innovative oncology treatments with an emphasis on improving the lives of children and adults living with cancer.
DAWN Company Deck
DAWN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with strong revenue growth, increased prescriptions, and positive clinical data. The raised revenue guidance and inclusion in NCCN guidelines further support a positive trajectory. However, the high gross-to-net ratio and limited impact of EAP patients were noted challenges.View all DAWN earnings summariesDAWN Stock 12 Month Forecast
Average Price Target
$23.57
▲(166.33% Upside)
Technical Analysis
Theravance Biopharma
―
Kura Oncology
―
Gossamer Bio
―
Maravai Lifesciences Holdings
―
Septerna, Inc.
―
Ownership Overview
4.19% Insiders
20.93% Mutual Funds
28.81% Other Institutional Investors
34.50% Public Companies and
Individual Investors